Patent 8664189 was granted and assigned to Rxi Pharmaceuticals Corporation on March, 2014 by the United States Patent and Trademark Office.
The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.